Oxaliplatin (generic name) is a platinum-based chemotherapy drug used in the treatment of bowel cancer (colorectal cancers). Side effects of oxaliplatin treatment can potentially include severe peripheral neuropathy such as numbness or tingling.
NanoCarrier has been working with Debiopharm S.A., who developed oxaliplatin, to develop DACH-Platin micelles (a new platinum compound). DACH-Platin is an active metabolite of oxaliplatin, which shows stronger anticancer activity. By using coordination bonds to polyamino acid, we have prepared micellar nanoparticles containing DACH-Platin derivatives that has stronger anticancer efficacy with lower side effects.
The basic technology of this formulation was invented by Professor Kataoka of the University of Tokyo. The technology was licensed in from TOUDAI TLO Ltd. The basic Japanese patent has been granted as Patent No. 39955992.
NanoCarrier has been working with Debiopharm S.A., who developed oxaliplatin, to develop DACH-Platin micelles (a new platinum compound). DACH-Platin is an active metabolite of oxaliplatin, which shows stronger anticancer activity. By using coordination bonds to polyamino acid, we have prepared micellar nanoparticles containing DACH-Platin derivatives that has stronger anticancer efficacy with lower side effects.
The basic technology of this formulation was invented by Professor Kataoka of the University of Tokyo. The technology was licensed in from TOUDAI TLO Ltd. The basic Japanese patent has been granted as Patent No. 39955992.
